These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Goldstone AH; Burnett AK; Wheatley K; Smith AG; Hutchinson RM; Clark RE; Blood; 2001 Sep; 98(5):1302-11. PubMed ID: 11520775 [TBL] [Abstract][Full Text] [Related]
25. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML. de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416 [TBL] [Abstract][Full Text] [Related]
26. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Zittoun R; Jehn U; Fière D; Haanen C; Löwenberg B; Willemze R; Abels J; Bury J; Peetermans M; Hayat M Blood; 1989 Mar; 73(4):896-906. PubMed ID: 2645950 [TBL] [Abstract][Full Text] [Related]
27. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356 [TBL] [Abstract][Full Text] [Related]
28. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631 [TBL] [Abstract][Full Text] [Related]
29. Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long-term maintenance chemotherapy. Machover D; Rappaport H; Schwarzenberg L; Misset JL; Goldschmidt E; Lemaigre G; Dorval T; De Vassal F; Ribaud P; Gaget H Cancer; 1984 Apr; 53(8):1644-50. PubMed ID: 6582996 [TBL] [Abstract][Full Text] [Related]
33. [Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia]. Taguchi H; Kubonishi I; Takehara N; Uemura Y; Iwahara Y; Eguchi T; Miyagi T; Sugito S; Muneishi H; Tanaka Y Gan To Kagaku Ryoho; 1992 Aug; 19(9):1309-14. PubMed ID: 1503485 [TBL] [Abstract][Full Text] [Related]
34. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Dillman RO; Davis RB; Green MR; Weiss RB; Gottlieb AJ; Caplan S; Kopel S; Preisler H; McIntyre OR; Schiffer C Blood; 1991 Nov; 78(10):2520-6. PubMed ID: 1824249 [TBL] [Abstract][Full Text] [Related]
35. Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study. Ogata K; An E; Kamikubo K; Yokose N; Tamura H; Yamada T; Gomi S; Dan K; Nomura T Stem Cells; 1998; 16(4):280-7. PubMed ID: 9708450 [TBL] [Abstract][Full Text] [Related]
36. Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen. Beguin Y; Sautois B; Forget P; Bury J; Fillet G Cancer; 1997 Apr; 79(7):1351-4. PubMed ID: 9083157 [TBL] [Abstract][Full Text] [Related]
37. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute]. Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012 [TBL] [Abstract][Full Text] [Related]
38. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Liu Yin JA; Wheatley K; Rees JK; Burnett AK; Br J Haematol; 2001 Jun; 113(3):713-26. PubMed ID: 11380463 [TBL] [Abstract][Full Text] [Related]
39. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Fopp M; Fey MF; Bacchi M; Cavalli F; Gmuer J; Jacky E; Schmid L; Tichelli A; Tobler A; Tschopp L; Von Fliedner V; Gratwohl A Ann Oncol; 1997 Mar; 8(3):251-7. PubMed ID: 9137794 [TBL] [Abstract][Full Text] [Related]
40. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]